Loading
Oruka Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Venrock Healthcare Capital Partners III, L.P., was filed 27 Feb 2025.
Insider Decl.
261
Thresholds
n/a
Buy Volume
€5M
56 ops. · all time
Sell Volume
€30M
130 ops. · all time
Who traded when
BuySaleJoana Goncalves33 sales
Arjun Agarwal26 sales
Paul T. Quinlan17 sales
Sandler Laura Lee15 sales
Lawrence Otto Klein8 sales
Venrock Healthcare Capital Partners III, L.P.5 buys
+1 other insider
Since the insiders bought
- +231.9%Entry US$10.15 · Close at T+365 US$33.69
- -68.2%Entry US$46.44 · Close at T+365 US$14.79
- -13.7%Entry US$28.92 · Close at T+365 US$24.96
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Oruka Therapeutics, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$155.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$79.92
Analyst consensus
12 analystsStrong buy
US$117.00Target US$155.00(+94%)US$200.00
Income statement
EBITDA-US$105.4M
Net income-US$105.4M0.0% margin
Valuation
PER (forward)-27.9x
P/Book4.4x
Beta-0.11
Balance sheet & cash
Market capUS$5.3B
Total debtUS$1.9M
Free Cash Flow-US$88.4M
Debt / Equity0%
Profitability & ownership
ROE-18.2%
ROA-13.0%
% insiders1.3%
% institutions116.9%
Last declaration on 20 October 2026
Declarations261 total
500 shares@ US$76.1180.0008% mcap0.5% of flowCommon StockSEC:0000907654-26-000110:2
1,000 shares@ US$77.2050.0016% mcap1.0% of flowCommon StockSEC:0000907654-26-000110:3
4,100 shares@ US$78.78950.0066% mcap4.1% of flowCommon StockSEC:0000907654-26-000110:4
9,000 shares@ US$7.800.0014% mcap0.9% of flowCommon StockSEC:0000907654-26-000110:0
400 shares@ US$74.90070.0006% mcap0.4% of flowCommon StockSEC:0000907654-26-000110:1
3,000 shares@ US$79.49120.0048% mcap3.0% of flowCommon StockSEC:0000907654-26-000110:5
21,000 shares@ US$76.680.030% mcap100.0% of flowCommonSEC144:0001950047-26-010266
3,500 shares@ US$6.840.0004% mcap0.7% of flowCommon StockSEC:0000907654-26-000108:0
3,500 shares@ US$7.800.0005% mcap0.8% of flowCommon StockSEC:0000907654-26-000108:1
2,853 shares@ US$73.88940.0039% mcap6.2% of flowCommon StockSEC:0000907654-26-000108:2
1,847 shares@ US$74.69240.0025% mcap4.1% of flowCommon StockSEC:0000907654-26-000108:3
1,400 shares@ US$75.48340.0019% mcap3.1% of flowCommon StockSEC:0000907654-26-000108:4
700 shares@ US$76.66520.0010% mcap1.6% of flowCommon StockSEC:0000907654-26-000108:5
200 shares@ US$77.710.0003% mcap0.5% of flowCommon StockSEC:0000907654-26-000108:6
9,999 shares@ US$82.110.015% mcap100.0% of flowCommonSEC144:0001950047-26-010177
1,458 shares@ US$34.390.0009% mcap1.2% of flowCommon StockSEC:0000907654-26-000106:1
5,741 shares@ US$80.03020.0084% mcap10.8% of flowCommon StockSEC:0000907654-26-000106:2
2,100 shares@ US$80.76010.0031% mcap4.0% of flowCommon StockSEC:0000907654-26-000106:3
8,541 shares@ US$12.500.0020% mcap2.5% of flowCommon StockSEC:0000907654-26-000106:0
1,958 shares@ US$81.85510.0029% mcap3.8% of flowCommon StockSEC:0000907654-26-000106:4
200 shares@ US$82.8350.0003% mcap0.4% of flowCommon StockSEC:0000907654-26-000106:5
200 shares@ US$84.780.0003% mcap0.2% of flowCommon StockSEC:0000907654-26-000104:3
16,246 shares@ US$83.39790.025% mcap13.7% of flowCommon StockSEC:0000907654-26-000104:1
8,554 shares@ US$84.02560.013% mcap7.3% of flowCommon StockSEC:0000907654-26-000104:2
25,000 shares@ US$7.800.0036% mcap2.0% of flowCommon StockSEC:0000907654-26-000104:0
25 of 261 declarations
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc. is a US healthcare and pharma company with a market value of USD 4.9 billion, and 154 of its 261 filings date from 2026. Over the last twelve months the record shows 160 filings, of which 102 sales and no purchase.
The largest sale is by Lawrence Otto Klein, Chief Executive Officer: EUR 5,031,888 on September 1, 2026. Carl Dambkowski, Director, sold EUR 2,718,242 and then EUR 1,926,482 on May 21, 2026. In all, 139 sales add up to EUR 35.2 million (median EUR 82,952).
Read moreShow less
The 56 purchases total EUR 5.3 million, with a median of EUR 52,837, or 29% of open-market trades. Funicular Fund, LP, with no role listed, filed 26 times, all purchases. Venrock Healthcare Capital Partners III, L.P., a 10% Owner, bought EUR 970,976 on February 14, 2025, and Janus Henderson Group PLC bought EUR 546,232 on July 3, 2024 and EUR 487,106 on July 24, 2024.
Joana Goncalves, Chief Medical Officer, files most often with 53 filings, 33 of them sales. Filings run from March 2, 2016 to October 20, 2026. For the 56 purchases with a result, the 90-day median is 0%, with 48% of results positive (recorded past results, not a forecast).
